Trial reportAmerican journal of clinical dermatology2018
Prevention and Reduction of Atrophic Acne Scars with Adapalene 0.3%/Benzoyl Peroxide 2.5% Gel in Subjects with Moderate or Severe Facial Acne: Results of a 6-Month Randomized, Vehicle-Controlled Trial Using Intra-Individual Comparison.
Trial report in American journal of clinical dermatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Adapalene 0.3% - Benzoyl Peroxide 2.5% Gel Versus Vehicle Gel on the Risk of Formation of Atrophic Acne Scars in Moderate to Severe Acne Subjects
A Randomized Controlled Trial of Efficiency of Moisturizer Containing Licochalcone A, Decanediol, L-carnitine and Salicylic Acid in Reducing Relapsing of Acne in Thai Acne Subjects
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 68 citations in OpenAlex.
- Identifying and appraising patient-reported outcome measures on treatment satisfaction in acne: a systematic review.The British journal of dermatology · 2021Pooled it
- Topical benzoyl peroxide for acne.The Cochrane database of systematic reviews · 2020Pooled it
- Clinical implications of skincare: lessons from placebo-controlled dermatology trials.Skin health and disease · 2026Review
- Impulsivity, Psychological Distress, and Quality of Life Among the Patients With Acne Vulgaris: Factors Related to Acne Scars.Journal of cosmetic dermatology · 2026Article
- Acne tarda: Recommendations for classification, treatment and care as a result of an expert discussion.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2026Review
- An Assessment of Current Clinician- and Patient-Reported Outcome Measures for Acne Scarring and Dyspigmentation: A Scoping Review.The Journal of investigative dermatology · 2025Article
- PRACT-India: Practical Recommendations on Acne Care and Medical Treatment in India-A Modified Delphi Consensus.Antibiotics (Basel, Switzerland) · 2025Article
- Scar Management in Pediatric Patients.Medicina (Kaunas, Lithuania) · 2025Review
- A Real-World Approach to Trifarotene Treatment in Patients with Acne and Acne Sequelae Based on the Experience of the Italian Acne Board.Dermatology and therapy · 2025Article
- Antibacterial activity and impact on keratinocyte cell growth ofCurrent research in microbial sciences · 2025Article
- The synergistic effects of Guaiacum officinale and Rhodomyrtus tomentosa extracts in the treatment of acne vulgaris on sensitive skin.Journal of cosmetic dermatology · 2024Article
- Review
- Article
- Review
- Liposomes and Other Nanocarriers for the Treatment of Acne Vulgaris: Improved Therapeutic Efficacy and Skin Tolerability.Pharmaceutics · 2024Review
- Evidence-based management of cutaneous scarring in dermatology part 2: atrophic acne scarring.Archives of dermatological research · 2023Review
- Trifarotene Reduces Risk for Atrophic Acne Scars: Results from A Phase 4 Controlled Study.Dermatology and therapy · 2023Article
- Acne treatment challenges - Recommendations of Latin American expert consensus.Anais brasileiros de dermatologiaReview
- Maintenance Acne Treatment with Topical Tazarotene after Oral Isotretinoin: Overview and Case Reports.The Journal of clinical and aesthetic dermatologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVery few clinical trials have investigated the effect of topical acne treatment on scarring.
objectivesOur objective was to evaluate the efficacy of adapalene 0.3%/benzoyl peroxide 2.5% gel (A0.3/BPO2.5) in atrophic acne scar formation in patients with acne.
methodsIn this multicenter, randomized, investigator-blinded, vehicle-controlled study, subjects with moderate or severe facial acne (Investigator's Global Assessment [IGA] score 3 or 4; ≥ 25 inflammatory lesions; ten or more atrophic acne scars) applied A0.3/BPO2.5 or vehicle daily per half face for 24 weeks. Subjects with acne requiring systemic treatment were excluded. Assessments included investigator atrophic acne scar count, Scar Global Assessment (SGA), acne lesion count, IGA, skin roughness and skin texture, subject self-assessment of clinical acne-related scars and satisfaction questionnaire, tolerability, and safety.
resultsIncluded subjects (n = 67) had mainly moderate acne (92.5% IGA 3); mean scores at baseline were approximately 40 acne lesions and 12 scars per half face. By week 24, the change from baseline in total scar count was - 15.5% for A0.3/BPO2.5 versus + 14.4% for vehicle (approximately 30% difference), with a mean of 9.5 scars versus 13.3 per half face, respectively (p < 0.0001). For SGA at week 24, a total of 32.9% with A0.3/BPO2.5 versus 16.4% with vehicle (p < 0.01) were clear/almost clear. Inflammatory acne lesions decreased by 86.7% for A0.3/BPO2.5 versus 57.9% for vehicle (p < 0.0001), and 64.2 versus 19.4% of subjects, respectively, were IGA clear/almost clear (p < 0.0001) at week 24. Treatment-related AEs were reported by 20.9% for A0.3/BPO2.5 versus 9% for vehicle side, most commonly skin irritation (14.9 vs. 6%, respectively).
conclusionsTopical A0.3/BPO2.5 prevented and reduced atrophic scar formation. Scar count increased with vehicle (+ 14.4%) but decreased with A0.3/BPO2.5 (- 15.5%) over 24 weeks. TRIAL REGISTRY: ClinicalTrials.gov identifier NCT02735421.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.